The present disclosure relates to the treatment of HPV-associated cancers by small molecule PD-L1 inhibitors.

A method for initiating a telemedicine conference on a mobile device is provided. The method comprises receiving diagnostic test results in response to a diagnostic test, determining if the diagnostic test results include a positive result, storing the diagnostic test results on a server disposed on a network, presenting, if the diagnostic test results are positive, a telemedicine initiation option on a screen of the mobile device, determining whether the telemedicine initiation option is selected, sending the diagnostic test results from the server to the telemedicine provider, sending additional medical history information to the telemedicine provider, and initiating a telemedicine conference with the telemedicine provider. Some of these aspects also provide healthcare providers the ability to electronically send prescriptions and provide users the ability to use a mobile application to send prescriptions to pharmacies to be filled.

The present invention relates to a fusion protein comprising: —a N-terminal domain which comprises an antibody which is a variable domain of a camelid heavy-chain antibody (VHH) or a single chain variable fragment (scFV) and which is directed against an immunoglobulin and —a C-terminal domain which comprises a polypeptide with a luciferase activity: —having the amino acid sequence SEQ ID NO: 1 or —having at least 80% amino acid sequence identity to the amino acid sequence SEQ ID NO: 1.

A diagnostic system for determining the presence of a target in a sample liquid that includes a diagnostic reader and a microfluidic strip having a microfluidic channel network therein. An actuator within the reader modifies the pressure of a gas in gaseous communication with a liquid-gas interface of a sample liquid within the microfluidic channel network to move and/or mix the sample liquid. The pressure modifications may be continuous and/or oscillatory.

The present disclosure provides an isolated or purified SARS-CoV-2 Receptor Binding Domain (RBD) polypeptide and cells for producing such a polypeptide, as well as compositions and methods thereof.

The present invention relates to lateral flow assay devices adapted to detect IgA specific for SARS-CoV-2 in biological samples from subjects suspected to have COVID-19, and methods of using the lateral flow assay devices.

The invention provides methods and compositions for assaying infectivity of viruses and potential treatments of such viruses in the upper respiratory tract using an air-liquid interface model with nasal epithelium cells; and treatment of viral infections of the upper respiratory tract by treating with bitter taste receptor agonists that stimulate NO production and/or antimicrobial protein production.

The present invention provides systems, devices, and methods for point-of-care and/or distributed testing services. The methods and devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device can be modified to allow for more flexible and robust use with the disclosed methods for a variety of medical, laboratory, and other applications. The systems, devices, and methods of the present invention can allow for effective use of samples by improved sample preparation and analysis.

An apparatus is provided for airborne pathogen detection, which includes a crystal microbalance. The apparatus includes specific capture probes that are affixed to the crystal microbalance and are designed to bind to and capture a specific pathogen, such as a virus particle. This capture causes a change in mass of the crystal microbalance that can be detected. A method is provided for airborne pathogen detection, which includes calibrating a resonant frequency of the crystal microbalance to a mass on the crystal microbalance. The method also includes a step of conjugating the antibody to the crystal microbalance. The method also includes, for each measurement time, measuring a resonant frequency of the crystal microbalance and determining a mass change due to binding of the pathogen to the detector. This mass change is then related to pathogen load in the medium. A notification is output if the viral load exceeds a predetermined threshold.

Disclosed is a kit for testing a COVID-19 antigen. The kit includes a test card, a conjugate pad and a reaction pad being arranged on the test card; wherein the conjugate pad is provided with a labeled antibody Ab1 and a labeled antibody Ab3 of the COVID-19 antigen, and a quality control line and a test line are arranged in parallel with an interval on the reaction pad, the test line being provided with a coating antibody Ab2, and the quality control line being provided with a coating antibody Ab4. With the kit, by the AIE immunofluorescence chromatographic technique, the AIE fluorescent microspheres are used as labels, and the test result of the test card is directly determined and read by using a fluorescent flashlight, or the test result is read by using a fluorescent tester. Such kits have the advantages of high sensitivity, strong specificity and simple operation.